Adverse Drug Reactions in Patients with CKD
JACQUELINET, Christian
Agence de la biomédecine [Saint-Denis la Plaine]
Centre de recherche en épidémiologie et santé des populations [CESP]
Agence de la biomédecine [Saint-Denis la Plaine]
Centre de recherche en épidémiologie et santé des populations [CESP]
COMBE, Christian
Centre Hospitalier Universitaire de Bordeaux [CHU Bordeaux]
Bioingénierie tissulaire [BIOTIS]
Centre Hospitalier Universitaire de Bordeaux [CHU Bordeaux]
Bioingénierie tissulaire [BIOTIS]
FRIMAT, Luc
Maladies chroniques, santé perçue, et processus d'adaptation [APEMAC]
Service de Néphrologie [CHRU Nancy]
Maladies chroniques, santé perçue, et processus d'adaptation [APEMAC]
Service de Néphrologie [CHRU Nancy]
MASSY, Ziad
Centre de recherche en épidémiologie et santé des populations [CESP]
Service Néphrologie/Dialyse [AP-HP Ambroise-Paré]
Centre de recherche en épidémiologie et santé des populations [CESP]
Service Néphrologie/Dialyse [AP-HP Ambroise-Paré]
LIABEUF, Sophie
Mécanismes physiopathologiques et conséquences des calcifications cardiovasculaires - UR UPJV 7517 [MP3CV]
CHU Amiens-Picardie
< Réduire
Mécanismes physiopathologiques et conséquences des calcifications cardiovasculaires - UR UPJV 7517 [MP3CV]
CHU Amiens-Picardie
Langue
en
Article de revue
Ce document a été publié dans
Clinical Journal of the American Society of Nephrology. 2020, vol. 15, n° 8, p. 1090-1102
American Society of Nephrology
Résumé en anglais
Background and objectives Little is known about the burden of adverse drug reactions in CKD. We estimated the incidence of overall and serious adverse drug reactions and assessed the probability of causation, preventability, ...Lire la suite >
Background and objectives Little is known about the burden of adverse drug reactions in CKD. We estimated the incidence of overall and serious adverse drug reactions and assessed the probability of causation, preventability, and factors associated with adverse drug reactions in patients seen by nephrologists.Design, setting, participants, & measurements The Chronic Kidney Disease-Renal Epidemiology and Information Network cohort included 3033 outpatients (65% men) with CKD and eGFR<60 ml/min per 1.73 m2, with follow-up for 2 years. Adverse drug reactions were identified from hospitalization reports, medical records, and participant interviews and finally assessed for causality, preventability, and immediate therapeutic management by experts in pharmacology.Results Median (interquartile range) age was 69 (60–76) years old; 55% had eGFR≥30 ml/min per 1.73 m2, and 45% had eGFR<30 ml/min per 1.73 m2. Participants were prescribed a median (range) of eight (five to ten) drugs. Over 2 years, 536 patients had 751 adverse drug reactions, 150 (in 125 participants) classified as serious, for rates of 14.4 (95% confidence interval, 12.6 to 16.5) and 2.7 (95% confidence interval, 1.7 to 4.3) per 100 person-years, respectively. Among the serious adverse drug reactions, 32% were considered preventable or potentially preventable; 16 caused death, directly or indirectly. Renin-angiotensin system inhibitors (15%), antithrombotic agents (14%), and diuretics (10%) were the drugs to which the most adverse drug reactions were imputed, but antithrombotic agents caused 34% of serious adverse drug reactions. The drug was discontinued in 71% of cases, at least temporarily. Adjusted hazard ratios for serious adverse drug reaction were significantly higher in patients with eGFR<30 versus ≥30 ml/min per 1.73 m2 (1.8; 95% confidence interval, 1.3 to 2.6), in those prescribed more than ten versus less than five medications (2.4; 95% confidence interval, 1.1 to 5.2), or in those with poor versus good adherence (1.6; 95% confidence interval, 1.4 to 2.4).Conclusions Adverse drug reactions are common and sometimes serious in patients with CKD. Many serious adverse drug reactions may be preventable. Some specific pharmacologic classes, particularly antithrombotic agents, are at risk of serious adverse drug reactions< Réduire
Mots clés en anglais
Pharmacoepidemiology
renin-angiotensin system inhibitors
antithrombotic agents
diuretics
chronic kidney disease
adverse drug reaction
Origine
Importé de halUnités de recherche